Slate Medicines appoints Mark W. Hahn to its board of directors

The biotech company said Hahn brings more than 25 years of life sciences experience, including steering companies through financial milestones and FDA approvals.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.